Highlights Alligator Bioscience AB London S.E.

Equities

0RK9

SE0000767188

Market Closed - London S.E. Other stock markets 15:52:01 17/11/2021 GMT			After market 16:25:00
2.508 ^SEK	-66.28%		1.126	-55.11%

03:13pm	Alligator Bioscience Names New CFO	MT
06-03	Alligator Bioscience Announces Publication of on Its Lead Drug Candidate Positive Phase 2 Data Mitazalimab in First Line Metastatic Pancreatic Cancer in the Lancet Oncology	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alligator Bioscience Announces Publication of on Its Lead Drug Candidate Positive Phase 2 Data Mitazalimab in First Line Metastatic Pancreatic Cancer in the Lancet Oncology	06-03	CI
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting	05-23	CI
Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer	05-14	CI
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	04-26	CI
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs	03-26	CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	03-07	CI
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-08	CI
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation	02-08	CI
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer	01-29	CI
Alligator Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23	CI
Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab	12/10/23	CI
Alligator Bioscience Obtains Orphan Status for Pancreatic Cancer Therapy in EU	21/08/23	MT
Alligator Bioscience Advances Research Partnership With Orion	31/07/23	MT
Alligator Bioscience AB Announces Technical Feasibility in the Second Program Under the Research Collaboration and License Agreement with Orion Corporation	31/07/23	CI
Alligator Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/07/23	CI
Alligator Bioscience AB Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist	30/06/23	CI
Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer	26/06/23	CI
Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023	05/06/23	CI
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alligator Bioscience AB London S.E.

Equities

0RK9

SE0000767188

Highlights

Filters